Amicus Therapeutics Inc (FRA:AM6)
€ 9.3 0.2 (2.2%) Market Cap: 2.82 Bil Enterprise Value: 3.01 Bil PE Ratio: 0 PB Ratio: 16.43 GF Score: 78/100

Amicus Therapeutics Inc and the University of Pennsylvania Expansion of Gene Therapy Collaboration - Call Transcript

May 29, 2019 / 12:30PM GMT
Release Date Price: €10.47 (-2.33%)
Operator

Good day, ladies and gentlemen, and welcome to the Amicus Therapeutics and the University of Pennsylvania expansion of gene therapy collaboration conference call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to introduce your host for today's conference, Ms. Sara Pellegrino, Vice President, Investor Relations and Corporate Communications. Ma'am, you may begin.

Sara Pellegrino
Amicus Therapeutics, Inc. - VP of IR & Corporate Communications

Good morning. Thank you for joining our conference call to discuss the Amicus Therapeutics' expanded gene therapy collaboration with the University of Pennsylvania. Speaking on today's call, we have John Crowley, Chairman and Chief Executive Officer of Amicus; Dr. Jim Wilson of the Gene Therapy Program in the Perelman School of Medicine at Penn; and Dr. Hung Do, Chief Science Officer at Amicus. Also joining for Q&A from Amicus are: Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; Dr. Jeff Castelli, Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot